For the fourth quarter, the point-of-care diagnostics company anticipates revenues of between $25 million and $28 million.

Parent firm Siemens is considering reducing its ownership stake in Siemens Healthineers, which could mean the termination of existing financing agreements.

The firm said that growth in its immunodiagnostics business was offset by contraction in its molecular diagnostics, licensed technologies, and COVID-19 businesses.

The company reported flat overall revenues compared to Q4 2024 as gains in its imaging segment were offset by declines in its other businesses.

The firm's data and services revenues grew 26 percent to $81.3 million, while genomics revenues more than doubled to $252.9 million.

These drugs, which are among the most common types of blood thinners, can interfere with traditional coagulation tests, producing unreliable results.